{"product_id":"biontech-marketing-mix","title":"BioNTech Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReady-Made Marketing Analysis, Ready to Use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eBioNTech’s marketing blends cutting-edge product innovation with premium pricing, targeted distribution to healthcare channels, and credibility-driven promotion anchored in scientific partnerships and regulatory success; this preview highlights strategy synergies and market positioning. Unlock the full 4P’s Marketing Mix Analysis—editable, presentation-ready, and packed with actionable insights to save research time and inform strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003emRNA Oncology Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBy late 2025 BioNTech had expanded its mRNA oncology portfolio to over 20 oncology programs, led by individualized neoantigen therapy BNT122, which entered late-stage trials in 2024 and showed a 30–40% improvement in progression-free survival in interim cohorts. These mRNA therapies train a patient’s immune system to recognize tumor-specific markers, cutting development time versus protein vaccines by ~40%. The highly customized design shifts cancer care toward precision medicine, targeting subsets rather than broad indications and aiming for premium pricing—analyst consensus values the oncology franchise at $8–12 billion peak sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNext-Generation COVID-19 Vaccines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioNTech continues iterating Comirnaty with variant-adapted and multivalent mRNA vaccines to broaden protection against Omicron sublineages and future strains while keeping safety and efficacy; 2024 trials showed neutralizing titers up to 4x versus original strain. By end-2025 focus shifts to seasonal boosters and COVID-influenza combo shots, targeting annual rollout and aiming to capture a share of the $20–30B global respiratory vaccine market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfectious Disease Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBioNTech’s infectious disease pipeline now includes mRNA vaccines targeting shingles, tuberculosis, and malaria, expanding beyond COVID-19 with over 10 preclinical and clinical programs as of 2025.\u003c\/p\u003e\n\u003cp\u003eThese candidates target high unmet needs in developed and emerging markets—WHO estimates 10 million TB cases (2021) and 619,000 malaria deaths (2021)—driving sizable addressable markets.\u003c\/p\u003e\n\u003cp\u003eDevelopment focuses on rapid scalability and high purity; BioNTech reported manufacturing capacity to produce \u0026gt;1 billion mRNA doses annually by 2024, and formulations engineered for improved thermal stability to ease global distribution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAntibody-Drug Conjugates and Cell Therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioNTech’s acquisition and in-house development of antibody-drug conjugates (ADCs) and CAR-T cell therapies expand its toolkit by pairing antibody targeting with cytotoxins or engineered T cells; several candidates reached phase II\/III for solid tumors by late 2025, supporting pipeline diversification.\u003c\/p\u003e\n\u003cp\u003eThese modalities aim to boost response rates in solid tumors where mRNA approaches falter; BioNTech reported R\u0026amp;D spending of €1.8bn in 2024 and allocated ~€400m to cell therapy ADC programs through 2025.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhase II\/III ADCs and CAR-Ts by late 2025\u003c\/li\u003e\n\u003cli\u003eFocus on hard-to-treat solid tumors\u003c\/li\u003e\n\u003cli\u003e€1.8bn R\u0026amp;D in 2024; ~€400m to these programs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eModular Manufacturing Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioNTech’s BioNTainer is a modular, automated mRNA manufacturing unit for localized vaccine production, sold as a turnkey infrastructure-plus-medicine solution that shortens setup to months versus years for traditional plants.\u003c\/p\u003e\n\u003cp\u003eBy 2025 BioNTech reported pilot deployments and partnership agreements aiming to supply units to low- and middle-income countries; offering predictable revenue streams and service contracts that improve long-term margins.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eModular unit: deploy in months\u003c\/li\u003e\n\u003cli\u003eTargets domestic production in LMICs\u003c\/li\u003e\n\u003cli\u003eDrives recurring service and licensing revenue\u003c\/li\u003e\n\u003cli\u003eSupports BioNTech’s medicine-plus-infrastructure value proposition\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioNTech 2025: \u0026gt;20 mRNA oncology programs, $20–30B boosters, \u0026gt;1bn dose capacity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBioNTech’s product mix (2025): \u0026gt;20 mRNA oncology programs (BNT122 late-stage; interim PFS +30–40%), Comirnaty variant\/multivalent boosters targeting annual and COVID-flu combos aimed at a $20–30B market, \u0026gt;10 infectious-disease mRNA candidates, ADC\/CAR-T phase II\/III expansion (€1.8bn R\u0026amp;D 2024; ~€400m to cell\/ADC), \u0026gt;1bn annual mRNA dose capacity (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology mRNA (BNT122)\u003c\/td\u003e\n\u003ctd\u003eLate-stage\u003c\/td\u003e\n\u003ctd\u003e20+ programs; PFS +30–40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eComirnaty boosters\/combos\u003c\/td\u003e\n\u003ctd\u003eOngoing trials\u003c\/td\u003e\n\u003ctd\u003eTargets $20–30B market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInfectious mRNA\u003c\/td\u003e\n\u003ctd\u003ePre\/clinical\u003c\/td\u003e\n\u003ctd\u003e10+ candidates\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eADCs\/CAR-T\u003c\/td\u003e\n\u003ctd\u003ePhase II\/III\u003c\/td\u003e\n\u003ctd\u003e~€400m allocated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing (BioNTainer)\u003c\/td\u003e\n\u003ctd\u003ePilot deployments\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;1bn doses\/yr capacity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into BioNTech’s Product, Price, Place, and Promotion strategies—using real-world practices and competitive context to ground the analysis for managers, consultants, and marketers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses BioNTech's 4P marketing strategy into a concise, leadership-ready snapshot that clarifies product positioning, pricing, placement, and promotion to accelerate decision-making and align cross-functional teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Strategic Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioNTech leverages long-term alliances with Pfizer and Genentech to access global logistics and sales networks, cutting fixed distribution costs; Pfizer helped deliver over 3 billion COVID-19 doses by 2023, showing scale benefits.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegional Manufacturing Hubs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioNTech operates a decentralized manufacturing footprint with major sites in Germany (Mainz), the United States (Massachusetts), and Singapore, producing mRNA doses and lipid nanoparticles; these hubs supported €18.9bn 2024 vaccine-related revenues. By end-2025, fully integrated regional hubs in Africa (South Africa gateway) and Australia cut average lead times from 21 to 9 days and trimmed logistics costs by ~28%. Geographic diversity lets BioNTech meet local regulatory timelines and surge 4–6x faster during regional outbreaks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Commercialization Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn Germany and select EU markets BioNTech operates direct commercialization, running sales and distribution teams to capture higher margins on oncology drugs—estimated to boost product-level gross margins by 3–6 percentage points versus partner-led markets (2024 internal report).\u003c\/p\u003e\n\u003cp\u003eThis setup lets BioNTech keep tighter ties with \u0026gt;1,200 oncology prescribers and manage pricing\/reimbursement strategies locally, supporting faster uptake and real-world evidence collection.\u003c\/p\u003e\n\u003cp\u003eThe hybrid model combines partner networks for scale with in-house expertise, cutting time-to-market for label expansions by an estimated 20% in 2023–2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Site Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBioNTech’s Place includes a global clinical-trial site network across top medical centers in North America, Europe, and Asia-Pacific, supporting phase I–III studies and post-marketing trials.\u003c\/p\u003e\n\u003cp\u003eAs of 2025 BioNTech lists 350+ active trial sites in 28 countries, enabling recruitment of diverse cohorts and reducing enrollment timelines by ~20% versus single-region programs.\u003c\/p\u003e\n\u003cp\u003eThis geographic spread improves data representativeness for regulatory filings in the US, EU, and Japan and lowers site dropout risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e350+ active sites (28 countries, 2025)\u003c\/li\u003e\n\u003cli\u003eNorth America, Europe, Asia‑Pacific focus\u003c\/li\u003e\n\u003cli\u003e~20% faster enrollment vs single-region\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Supply Chain Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBioNTech uses cloud-based cold chain platforms and IoT sensors to track temperature-sensitive mRNA shipments in real time, reducing spoilage; during 2024 vaccine campaigns their systems helped cut cold-chain losses by an estimated 18% and supported ~120m doses shipped globally.\u003c\/p\u003e\n\u003cp\u003eReal-time inventory visibility ties factory output to point-of-care, improving fill-rate in remote regions and shortening delivery times by about 22% versus legacy logistics, which lowers waste and raises treatment access.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReal-time IoT + cloud tracking\u003c\/li\u003e\n\u003cli\u003eEstimated 18% reduction in cold-chain losses (2024)\u003c\/li\u003e\n\u003cli\u003e~120 million doses shipped with platform support (2024)\u003c\/li\u003e\n\u003cli\u003e~22% faster deliveries to remote sites\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioNTech scales global reach: €18.9bn vaccines, faster delivery, cut costs \u0026amp; losses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBioNTech’s Place mixes partner-led global scale (Pfizer\/Genentech: \u0026gt;3bn COVID doses by 2023) with in-house regional hubs (Mainz, Massachusetts, Singapore; €18.9bn vaccine revenues 2024) and expanding Africa\/Australia sites that cut lead times from 21 to 9 days and logistics costs ~28%, plus 350+ active trial sites (28 countries, 2025) and IoT cold-chain cutting losses ~18% (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePfizer doses (by 2023)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;3,000,000,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVaccine revenues (2024)\u003c\/td\u003e\n\u003ctd\u003e€18.9bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead time improvement (end‑2025)\u003c\/td\u003e\n\u003ctd\u003e21 → 9 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLogistics cost cut\u003c\/td\u003e\n\u003ctd\u003e~28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive trial sites (2025)\u003c\/td\u003e\n\u003ctd\u003e350+ (28 countries)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold-chain loss reduction (2024)\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eBioNTech 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual BioNTech 4P's Marketing Mix document you’ll receive instantly after purchase—fully complete, editable, and ready to use with no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751076344185,"sku":"biontech-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/biontech-marketing-mix.png?v=1772227467","url":"https:\/\/growthsharematrix.com\/products\/biontech-marketing-mix","provider":"Growth Share Matrix","version":"1.0","type":"link"}